🇦🇷 Rompió la pared, emocionó al mundo entero. 🫶 🇦🇷 Selección Argentina ⭐⭐⭐ | #CopaMundialFIFA

⚡️ Molecular biomarkers of progression in non-muscle-invasive bladder cancer — beyond conventional risk stratification #BladderCancer OncoAlert nature.com/articles/s4158…

Si no tienes una pareja así mejor no tengas nada… Historia de amor de película: Tara Davis-Woodhall es campeona olímpica. Ahora, su marido, Hunter Woodhall, también se consagró en #Paris2024Paralympics .

"No puedo concebir una pérdida mayor que la pérdida de la autoestima". Mahatma Gandhi #Fuedicho

Terrific talk by Haval Balata about the UK mobile lung cancer screening experience!! Bring the lung health checks to the supermarket parking lots — 4.4% lung cancer detection rate. Haval Balata #WCLC24

#WCLC24 🙌🏼🇵🇾

San Diego ahora.....#WCLC24

Encuentro Argentino-Paraguayo en #WCLC24 🇦🇷🇵🇾🙌🏼🧬🩺🩻📝 Claudio Martin AgueroMiguel Kowalyszyn Ruben Diego Enrico Florencia Tsou

⚡️ Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection #BladderCancer OncoAlert Shilpa Gupta Hikmat Al Ahmadie Ashish M. Kamat, MD, MBBS

💫🌟Dear colleagues, 🚨 OncoAlert brings you our 🔟+1⃣ 👩‍🎓👨‍🎓MUST-SEE abstracts on #ProstateCancer to be presented at #ESMO24. 🚨 Stay tuned for the latest scientific breakthroughs! 👀 #OncoTwitter

PARP inhibitor maintenance in homologous recombination-proficient, advanced-stage epithelial #OvarianCancer needs careful risk-benefit analysis. A multidisciplinary team reviews this in a unique #VirtualTumorBoard: acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… OncoAlert #TumorBoardTuesday #gyncsm

Omitting the 5-FU bolus from regimens like FOLFOX, FOLFIRI, and FOLFIRINOX in metastatic GI cancers may reduce toxicity without impacting overall survival. #GIcancer #oncology #cancer @oncoalert ESMO - Eur. Oncology Mohamed E. Salem, MD, FASCO Kristen Ciombor Tanios Bekaii-Saab, MD Journal of the National Comprehensive Cancer Network (NCCN) @NCCN Mark Lewis, MD, FASCO

We presented in world lung our results of 331 patients with lung cancer having liquid and tissue NGS at the same time. 80% of the time 8 days later we can make a treatment decision based on liquid NGS only! Memorial Cancer Institute Memorial Healthcare System International Society of Liquid Biopsy Christian Rolfo Umberto Malapelle

V Congreso internacional de Oncología Médica 2024🇵🇾🙌🏼 30/31 octubre y 1 de nov

Quiero contarles que comienzo un nuevo desafío que me llena de orgullo, ser parte del equipo de difusión de IntraMed Oncología 💪🏻 Estaremos llevando el día a día de las actualizaciones en oncología 📝 por medio de las redes y la página web intramed.net

What??? Such a huge impact of the science that will be presented at #ESMO24 💪🔝🤩👏 Rebecca Dent Andres Cervantes ESMO - Eur. Oncology OncoAlert Annals of Oncology NEJM Nature Medicine The Lancet JAMA Network

Presidential symposium at #ESMO24 Practice changing trial ⚠️ ➡️ PEACE3: radium223 + enzalutamide in #mCRPC met 1️⃣ endpoint (rPFS) 3⃣ 1⃣ % reductions of risk ➡️ OS survival benenefit 42 months!! ⚠️Mandatory BPA silke gillessen IntraMed Oncología Asociación Argentina de Oncología Clínica (AAOC) Fundación Cáncer

🚨 Time to eliminate bolus 5FU from advanced GI #cancer protocols! JNCI The ASCO Post ➡️Flatiron data from almost 12k cases report less toxicity with comparable survival - validation of what most of us are already doing. 👍 OncoAlert

Peter Schmid presents the OS data from KN522 #ESMO24 publl now in NEJM. >6 year FU: 9% EFS benefit, 5% ⬆️OS with pembro pre/post op for TNBC. Pts with PCR had 95% survival +/-pembro but 6% ⬆️OS in nonPCR + pembro. Safety same. Huge advance for TNBC. Need biomarkers! OncoAlert

NIAGARA is the first randomized trial to demonstrate significant OS difference in the NIBC perioperative trest. #ESMO24 Tom Powles did it again!!! Another practice changing trial in the back OncoAlert ESMO - Eur. Oncology